Tradestie Institutional Equity Comparison Engine

PACS vs CON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CON Overall Edge

CON Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Concentra Group Holdings Parent, Inc. (CON) driven by superior Growth & Margin, Options & Structure while PACS counters with relative strength in Valuation, Momentum & Technical. Fundamentally, PACS trades at 15.3x Forward P/E with 7.4% operating margin (+11.5% YoY revenue) versus CON at 22.0x Forward P/E and 17.2% operating margin (+8.6% YoY). In options structure, PACS sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against CON sits in BREAKOUT (95th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PACS
PACS 15.3x vs CON 22.0x Fwd P/E
Growth & Margin Winner CON
Op Margin 7.4% vs 17.2% ยท YoY +11.5% vs +8.6%
Momentum & Technical Winner PACS
1Y +159.5% vs +117.6% ยท 52W Pos 79% vs 91%
Options & Structure Winner CON
CONSOLIDATION (11th %ile IV) vs BREAKOUT (95th %ile IV)
PACS NYSE
PACS Group, Inc.
Services-Skilled Nursing Care Facilities
$43.67
+1.49% 1D
Market Cap $6.8B
1M Return -8.06%
1Y Return +159.48%
Forward P/E 15.3x
Unified AI Score
46.8 / 100 HOLD
Tech 35.0 Fund 48.0 Flow 62.0 Mom 50.0
CON NYSE
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
1M Return +4.68%
1Y Return +117.58%
Forward P/E 22.0x
Unified AI Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PACS +159.48% CON +117.58% Spread: +41.9 pp (PACS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PACS Revenue CON Revenue PACS Op. Margin CON Op. Margin Margin Edge
FY2022 $2.40B $1.72B 9.6% 15.0% CON
FY2023 $3.11B $1.84B 6.7% 15.6% CON
FY2024 $4.09B $1.90B 3.0% 16.0% CON
FY2025 $5.29B $2.16B 5.9% 15.4% CON

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PACS (4) vs CON (6)
Institutional Metric PACS CON Criterion Row Winner
Market Capitalization Scale $6.8B $5.2B Larger Scale PACS
Trailing P/E Ratio Valuation 26.2x 24.5x Lower Multiple CON
Forward P/E Ratio Valuation 15.3x 22.0x Lower Multiple PACS
Revenue Growth (YoY) Growth +11.5% +8.6% Higher Growth PACS
Operating Margin (TTM) Profitability 7.4% 17.2% Higher Margin CON
Net Profit Margin Profitability 4.9% 9.3% Higher Margin CON
Return on Equity (ROE) Capital Efficiency 26.5% 47.2% Higher ROE CON
52-Week Range Position Momentum 79% ($14โ€“$52) 91% ($19โ€“$44) Stronger Trend CON
Beta / 30D Volatility Risk Regime 0.78ฮฒ ยท 51% Vol 0.52ฮฒ ยท 38% Vol Lower Realized Risk CON
Unified Institutional Score Composite Signal 46.8 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite PACS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PACS vs CON Buy Guide
PACS CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live PACS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CON BREAKOUT
99d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 95th %ile
IV Regime Extreme (>80th %ile)
Live CON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PACS nor CON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.